Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury

被引：20

作者：

Asakawa, Masahiro ^{[1
]}

Mitsui, Hiroshi ^{[2
]}

Akihisa, Momoko ^{[3
]}

Sekine, Tetsuo ^{[1
]}

Niitsu, Yoshihiro ^{[1
]}

Kobayashi, Arisa ^{[1
]}

Miyake, Atsuko ^{[1
]}

Hashimoto, Naoaki ^{[2
]}

Kawamura, Mitsunobu ^{[1
]}

Ogawa, Yoshihiro ^{[3
]}

机构：

[1] Tokyo Teishin Hosp, Dept Endocrinol & Metab, Chiyoda Ku, Tokyo 1020071, Japan

[2] Tokyo Teishin Hosp, Dept Gastroenterol, Chiyoda Ku, Tokyo 1020071, Japan

[3] Tokyo Med & Dent Univ Hosp, Dept Mol Endocrinol & Metab, Bunkyo Ku, Tokyo 1138510, Japan

来源：

SPRINGERPLUS | 2015年 / 4卷

关键词：

Dipeptidyl peptidase-4 inhibitor; Sitagliptin; Diabetes mellitus; Chronic liver injury; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; PEPTIDE-1; RECEPTOR; HEPATIC STEATOSIS; INCRETIN SYSTEM; CELL; DISEASE; HEPATOCYTES; FIBROSIS; GLP-1;

D O I：

10.1186/s40064-015-1135-z

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Aim: To investigate the efficacy and safety of a dipeptidyl peptidase-4 inhibitor, sitagliptin, for treating diabetes mellitus complicated by chronic liver injury. Methods: Sitagliptin was administered for 13.7 +/- 10.1 months to 122 patients with DM complicated by chronic liver injury (including 19 patients with liver cirrhosis), and changes in hemoglobin A1c (HbA1c) and liver enzymes (transaminases, etc.) were evaluated. Results: HbA1c was reduced from 8.48 +/- 1.43% to 7.87 +/- 1.35% (P < 0.001). Among liver enzymes, alanine aminotransferase (ALT) levels improved from 75.1 +/- 45.2 to 65.8 +/- 35.8 IU/L (P = 0.012) and gamma-glut amyl-trans peptidase from 155.2 +/- 161.1 to 133.2 +/- 127.4 IU/L (P = 0.044). Among the causes of liver injury, non-alcoholic fatty liver disease and alcoholic liver disease both showed the reductions in HbA1c with no deterioration of liver enzymes. An analysis of 19 patients with liver cirrhosis also showed reductions in HbA1c with no deterioration of liver enzymes. Conclusion: It is suggested that sitagliptin can be administered effectively and safely to patients with diabetes mellitus complicated by chronic liver injury, including liver cirrhosis.

引用

页数：7

共 30 条

[1] GLP-1 and extra-islet effects [J].

Ahrén, B .

HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) :842-845

[2] Dipeptidyl peptidase-4 inhibitors -: Clinical data and clinical implications [J].

Ahren, Bo .

DIABETES CARE, 2007, 30 (06) :1344-1350

[3] Nonalcoholic fatty liver disease [J].

Brunt, Elizabeth M. ;

Wong, Vincent W. -S. ;

Nobili, Valerio ;

Day, Christopher P. ;

Sookoian, Silvia ;

Maher, Jacquelyn J. ;

Bugianesi, Elisabetta ;

Sirlin, Claude B. ;

Neuschwander-Tetri, BrentA. ;

Rinella, Mary E. .

NATURE REVIEWS DISEASE PRIMERS, 2015, 1

[4] Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease [J].

Arase, Yasuji ;

Kawamura, Yusuke ;

Seko, Yuya ;

Kobayashi, Mariko ;

Suzuki, Fumitaka ;

Suzuki, Yoshiyuki ;

Akuta, Norio ;

Kobayashi, Masahiro ;

Sezaki, Hitomi ;

Saito, Satoshi ;

Hosaka, Tetsuya ;

Ikeda, Kenji ;

Kumada, Hiromitsu ;

Ohmoto-Sekine, Yuki ;

Hsieh, Shiun Dong ;

Amakawa, Kazuhisa ;

Ogawa, Kyoko ;

Matsumoto, Naoki ;

Iwao, Akiko ;

Tsuji, Hiroshi ;

Hara, Shigeko ;

Mori, Yasumichi ;

Okubo, Minoru ;

Sone, Hirohito ;

Kobayashi, Tetsuro .

HEPATOLOGY RESEARCH, 2013, 43 (11) :1163-1168

[5] Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus [J].

Arase, Yasuji ;

Suzuki, Fumitaka ;

Kobayashi, Mariko ;

Suzuki, Yoshiyuki ;

Kawamura, Yusuke ;

Matsumoto, Naoki ;

Akuta, Norio ;

Imai, Norihisa ;

Kobayashi, Masahiro ;

Sezaki, Hitomi ;

Saito, Satoshi ;

Hosaka, Tetsuya ;

Ikeda, Kenji ;

Kumada, Hiromitsu ;

Ohmoto, Yuki ;

Amakawa, Kazuhisa ;

Tsuji, Hiroshi ;

Hsieh, Shium Dong ;

Kobayashi, Tetsurou .

HEPATOLOGY RESEARCH, 2011, 41 (06) :524-529

[6] Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease [J].

Arase, Yasuji ;

Suzuki, Fumitaka ;

Ikeda, Kenji ;

Kumada, Hiromitsu ;

Tsuji, Hiroshi ;

Kobayashi, Tetsuro .

JOURNAL OF GASTROENTEROLOGY, 2009, 44 (10) :1064-1070

[7] Liver fibrosis [J].

Bataller, R ;

Brenner, DA .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) :209-218

[8] Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase [J].

Ben-Shlomo, Shani ;

Zvibel, Isabel ;

Shnell, Mati ;

Shlomai, Amir ;

Chepurko, Elena ;

Halpern, Zamir ;

Barzilai, Nir ;

Oren, Ran ;

Fishman, Sigal .

JOURNAL OF HEPATOLOGY, 2011, 54 (06) :1214-1223

[9] Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis [J].

Boettcher, E. ;

Csako, G. ;

Pucino, F. ;

Wesley, R. ;

Loomba, R. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (01) :66-75

[10] Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].

Browning, JD ;

Szczepaniak, LS ;

Dobbins, R ;

Nuremberg, P ;

Horton, JD ;

Cohen, JC ;

Grundy, SM ;

Hobbs, HH .

HEPATOLOGY, 2004, 40 (06) :1387-1395

← 1 2 3 →